BioSpace News Archive

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.

Alzheon CEO Dr. Martin Tolar Will Provide Overview of Company Business and Update on Oral Anti-Amyloid ALZ-801 Phase 3 Program in Alzheimer’s Disease

Enochian BioSciences today announced that it will be making a company presentation to investors at the upcoming H.C. Wainwright Global Life Sciences Conference.

Lyra Therapeutics, Inc. today announced the appointment of Jason Cavalier as Chief Financial Officer, effective today.

GT Biopharma, Inc. today, announces the advancement of GTB-3650 into IND-enabling studies, with which it plans to supplant the ongoing Phase 1 program with GTB-3550.

IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that the first peer reviewed article “Cryoablation Without Excision for Low-Risk, Early-Stage Breast Cancer: 3-Year Interim Analysis of Ipsilateral Breast Tumor Recurrence in the ICE3 Trial”

Palatin Technologies, Inc. today announced that Carl Spana , Ph.D., President and Chief Executive Officer, will participate in the H.C. Wainwright 23rd Annual Global Investment Virtual Conference on September 13-15, 2021.

AIVITA Biomedical, Inc. today announced results from its Phase 2 clinical study testing AIVITA’s anti-SARS-CoV-2 Vaccine Enabling Kit, which allows ny minimally-equipped facility to make personalized COVID-19 vaccines during the course of 2 patient visits one week apart.

Alkermes plc (Nasdaq: ALKS) today announced two poster presentations related to nemvaleukin alfa (nemvaleukin), the company’s novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the 2021 European Society for Medical Oncology (ESMO) Virtual Congress, taking place Sept. 16-21, 2021.

Results of a new multinational survey of healthcare providers revealed that the majority of participants expect immunotherapy to have a positive impact on the treatment landscape for patients with earlier-stage cancers in the adjuvant (after surgery), neo-adjuvant (before surgery) and peri-operative (both before and after surgery) settings, if approved by regulatory bodies.